ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Peptidream Inc.

  • 5,440.00 JPY
  • +30.00
  • +0.55%
  • Japan
    Mar 19, 2019
  • Ticker
    TKS(4587)
  • Prev. close
    5,410
  • Market cap (JPY)
    668,191.25M
  • Market cap (USD)
    6,004.86M
  • Shares
    123.51M

Business Summary

PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. It produces stable, and potent non-standard macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.

Financial Highlights

Jun 2018 JPYUSD
Revenue6,426.89M58.24M
Gross Profit4,580.75M41.51M
Operating income2,910.98M26.38M
Income before tax3,151.73M28.56M
Net income2,335.21M21.16M
EBITDA3,424.32M31.03M
Diluted EPS17.790.16
Dividends Per Share00
Total Assets16,502.26M148.98M
Total liabilities1,793.54M16.19M
Total equity14,708.71M132.79M
Operating cash flow1,022.71M9.26M
Currency in JPYCurrency in USD

Historical Data

 Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018
Revenue 818.90M 2,474.49M 4,327.87M 4,895.74M 6,426.89M
Gross Profit 503.67M 1,752.47M 3,241.08M 3,530.02M 4,580.75M
Operating income 201.36M 1,391.12M 2,548.08M 2,490.41M 2,910.98M
Income before tax 221.99M 1,493.37M 2,365.81M 2,624.15M 3,151.73M
Net income 148.51M 1,004.16M 1,581.28M 1,890.75M 2,335.21M
EBITDA 275.10M 1,494.19M 2,691.08M 2,685.28M 3,424.32M
Diluted EPS 1.36 7.83 12.26 14.56 17.79
Dividends Per Share 0 0 0 0 0
Total Assets 5,999.27M 7,738.44M 11,956.40M 13,628.45M 16,502.26M
Total liabilities 136.06M 826.01M 1,713.64M 1,447.65M 1,793.54M
Total equity 5,863.20M 6,912.43M 10,242.75M 12,180.80M 14,708.71M
Operating cash flow 72.17M 1,386.14M 1,533.05M 1,530.77M 1,022.71M
 Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018
Revenue 8.10M 21.58M 37.08M 44.87M 58.24M
Gross Profit 4.98M 15.28M 27.77M 32.35M 41.51M
Operating income 1.99M 12.13M 21.83M 22.82M 26.38M
Income before tax 2.19M 13.02M 20.27M 24.05M 28.56M
Net income 1.47M 8.76M 13.54M 17.33M 21.16M
EBITDA 2.72M 13.03M 23.05M 24.61M 31.03M
Diluted EPS 0.01 0.06 0.10 0.13 0.16
Dividends Per Share 0 0 0 0 0
Total Assets 59.21M 63.24M 116.54M 121.29M 148.98M
Total liabilities 1.34M 6.75M 16.70M 12.88M 16.19M
Total equity 57.87M 56.49M 99.84M 108.40M 132.79M
Operating cash flow 0.71M 12.09M 13.13M 14.03M 9.26M

Valuation Measures

Jun 2018
PER238.24
ROA15.50%
ROE17.36%
Operating margin45.29%
Profit margin36.33%

Key executives

  • President & Representative Director: Patrick Crawford Reid
  • Director, Manager-Research & Development: Keiichi Masuya
  • Manager-Public & Investor Relations: Toshiyuki Iwata

Shareholders

  • KUBOTA KIICHI (11.5%)
  • SUGA HIROAKI (8.8%)
  • J.O. Hambro Capital Management Ltd. (6.6%)
  • JPMorgan Asset Management (Japan) Ltd. (4.8%)
  • Asset Management One Co., Ltd. (3.9%)
  • REID PATRICK C (3.4%)
  • OppenheimerFunds, Inc. (2.4%)
  • Nomura Asset Management Co., Ltd. (2.0%)
  • Baillie Gifford & Co. (1.9%)
  • MURAKAMI HIROSHI /PEPTIDREAM INC/ (1.7%)

Contact Details

  • Website:http://peptidream.com
  • Address: 3-25-23 Tonomachi, Kawasaki-Ku, Kawasaki, 210-0821, Japan
  • Phone: +81.44.270.1300

Related Companies

  • Peptidream Board Incentive Plan
  • Peptidream Employee Incentive Plan
  • PharmaDesign, Inc. (Japan) /Pharma Research Bus/
  • PharmaDesign, Inc. (Japan)

Competitors

    Last Updated on 19 Mar, 2019

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends January 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media